ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AMRI lands a production deal

July 31, 2006 | APPEARED IN VOLUME 84, ISSUE 31

Albany Molecular Research Inc. has reached an agreement with New River Pharmaceuticals under which it will contract manufacture the active pharmaceutical ingredient in New River's NRP104, a treatment for attention deficit hyperactivity disorder currently under FDA review. New River collaborated with Shire on development of the compound and has a commercialization agreement with Shire as well.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment